These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 717456)

  • 1. Toxicity manifestations following intravenous Corynebacterium parvum administration to patients with ovarian and cervical carcinoma.
    Gall SA; DiSaia PJ; Schmidt H; Mittelstaedt L; Newman P; Creasman W
    Am J Obstet Gynecol; 1978 Nov; 132(5):555-60. PubMed ID: 717456
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Corynebacterium parvum toxicity in patients with limited and advanced malignancy.
    Hirshaut Y; Pinsky CM; Wanebo HJ; Braun DW
    Eur J Cancer Clin Oncol; 1984 May; 20(5):583-91. PubMed ID: 6539697
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase III study on the treatment of women with cervical cancer, stage IIB, IIIB, and IVA (confined to the pelvis and/or periaortic nodes), with radiotherapy alone versus radiotherapy plus immunotherapy with intravenous Corynebacterium parvum: a Gynecologic Oncology Group Study.
    DiSaia PJ; Bundy BN; Curry SL; Schlaerth J; Thigpen JT
    Gynecol Oncol; 1987 Mar; 26(3):386-97. PubMed ID: 3549476
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Value of immune monitoring in gynecologic cancer patients receiving immunotherapy.
    DiSaia PJ; Rich WM
    Am J Obstet Gynecol; 1979 Dec; 135(7):907-16. PubMed ID: 315714
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intraperitoneal immunotherapy of human ovarian carcinoma with Corynebacterium parvum.
    Bast RC; Berek JS; Obrist R; Griffiths CT; Berkowitz RS; Hacker NF; Parker L; Lagasse LD; Knapp RC
    Cancer Res; 1983 Mar; 43(3):1395-401. PubMed ID: 6825108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A preliminary study of intralesional, intralymph node, intravenous and intraperitoneal Corynebacterium parvum treatments in patients with advanced cancer.
    Cheng VS; Suit HD; Wang CC; Raker J; Weymuller E; Kaufman S
    Cancer; 1978 Oct; 42(4):1912-5. PubMed ID: 709538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Harmful effects of i.v. Corynebacterium Parvum given at the same time as cyclophosphamide in patients with squamous-cell carcinoma of the bronchus.
    von Blomberg BM; Glerum J; Croles JJ; Stam J; Drexhage HA
    Br J Cancer; 1980 Apr; 41(4):609-17. PubMed ID: 7387858
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Corynebacterium parvum as an immunotherapeutic agent in an ovarian cancer model.
    Knapp RC; Berkowitz RS
    Am J Obstet Gynecol; 1977 Aug; 128(7):782-6. PubMed ID: 560124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adverse effect of intrapleural Corynebacterium parvum as adjuvant therapy in resected stage I and II non-small cell carcinoma of the lung. Ludwig Lung Cancer Study Group.
    J Thorac Cardiovasc Surg; 1985 Jun; 89(6):842-7. PubMed ID: 2860271
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of advanced ovarian malignancy with chemoimmunotherapy using autologous tumor and Corynebacterium parvum.
    Gusdon JP; Homesley HD; Jobson VW; Muss HB
    Obstet Gynecol; 1983 Dec; 62(6):728-35. PubMed ID: 6633998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Observations following Corynebacterium parvum administration to patients with advanced malignancy. a phase I study.
    Fisher B; Rubin H; Sartiano G; Ennis L; Wolmark N
    Cancer; 1976 Jul; 38(1):119-30. PubMed ID: 947509
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activation of peritoneal lymphocyte cytotoxicity in patients with ovarian cancer by intraperitoneal treatment with Corynebacterium parvum.
    Lichtenstein A; Berek J; Bast R; Spina C; Hacker N; Knapp RC; Zighelboim J
    J Biol Response Mod; 1984 Aug; 3(4):371-8. PubMed ID: 6541243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nephrotoxicity from cancer immunotherapy.
    Dosik GM; Gutterman JU; Hersh EM; Akhtar M; Sonoda T; Horn RG
    Ann Intern Med; 1978 Jul; 89(1):41-6. PubMed ID: 666183
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of inflammatory neutrophils in antitumor effects induced by intraperitoneal administration of Corynebacterium parvum in mice.
    Lichtenstein AK; Berek J; Kahle J; Zighelboim J
    Cancer Res; 1984 Nov; 44(11):5118-23. PubMed ID: 6488171
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapy of a murine ovarian carcinoma with Corynebacterium parvum and specific heteroantiserum. I. Activation of peritoneal cells to mediate antibody-dependent cytotoxicity.
    Bast RC; Knapp RC; Mitchell AK; Thurston JG; Tucker RW; Schlossman SF
    J Immunol; 1979 Nov; 123(5):1945-51. PubMed ID: 489967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypercoagulability after immunotherapy with Corynebacterium parvum in man.
    Harenberg J; Baumgärtner A; Fritze D; Zimmermann R
    Blut; 1982 Apr; 44(4):241-7. PubMed ID: 7082858
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy for gynecologic malignancies.
    Cohen CJ; Deppe G
    Prog Clin Biol Res; 1981; 70():371-4. PubMed ID: 7031696
    [No Abstract]   [Full Text] [Related]  

  • 18. Adjuvant intralesional and systemic Corynebacterium parvum immunotherapy for surgically treated head and neck cancer.
    Beatty JD; Terz JJ; Brown PW; Lawrence W; Schuller GB; Kaplan AM
    Surg Forum; 1978; 29():155-7. PubMed ID: 401122
    [No Abstract]   [Full Text] [Related]  

  • 19. Intraperitoneal immunotherapy of epithelial ovarian carcinoma with Corynebacterium parvum.
    Berek JS; Knapp RC; Hacker NF; Lichtenstein A; Jung T; Spina C; Obrist R; Griffiths CT; Berkowitz RS; Parker L
    Am J Obstet Gynecol; 1985 Aug; 152(8):1003-10. PubMed ID: 2992276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intracavitary Corynebacterium parvum for treatment of malignant effusions.
    Currie JL; Gall S; Weed JC; Creasman WT
    Gynecol Oncol; 1983 Aug; 16(1):6-14. PubMed ID: 6884832
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.